IP Library › Granted Patent US 12,502,427
Granted Patent B2
US 12,502,427 · App. 17/441,524 · Granted Dec 23, 2025

Extracellular vesicles for vaccine delivery

Inventors: Raymond J. Moniz (Brighton, MA); Russell E. Mcconnell (Cambridge, MA); Nikki Ross (Philadelphia, PA); Christine Mccoy (Cambridge, MA); Timothy J. Soos (Boston, MA); Ke Xu (Belmont, MA)
Assignee: LONZA SALES AG
A61K39/385A61K39/00A61K39/0011A61P37/04A61K2039/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,427
App. No.
17/441,524
Granted
Dec 23, 2025
Kind
B2
Abstract

The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.

Claims (36)

1 . An isolated extracellular vesicle (EV) comprising (i) an antigen, (ii) a first scaffold moiety, and (iii) an adjuvant,

wherein the first scaffold moiety comprises a prostaglandin F2 receptor negative regulator (PTGFRN) protein or a fragment thereof.

2 . The EV of claim 1 , which comprises (i) at least 2 different antigens; (ii) at least 2 different adjuvants; or (iii) both (i) and (ii).

3 . The EV of claim 1 , which further comprises a second scaffold moiety.

4 . The EV of claim 3 , wherein the antigen, the adjuvant, or both the antigen and the adjuvant are linked to the first scaffold moiety, second scaffold moiety, or both.

5 . The EV of claim 3 , wherein the second scaffold moiety comprises a Scaffold Y or a Scaffold X.

6 . The EV of claim 5 , wherein: (i) the Scaffold X is selected from a prostaglandin F2 receptor negative regulator (the PTGFRN protein); basigin (BSG protein); immunoglobulin superfamily member 2 (IGSF2 protein); immunoglobulin superfamily member 3 (IGSF3 protein); immunoglobulin superfamily member 8 (IGSF8 protein); integrin beta-1 (ITGB1 protein); integrin alpha-4 (ITGA4 protein); 4F2 cell-surface antigen heavy chain (SLC3A2 protein); ATP transporter protein, or a fragment thereof, or any combination thereof; (ii) the Scaffold Y is selected from a myristoylated alanine rich Protein Kinase C substrate (MARCKS protein); myristoylated alanine rich Protein Kinase C substrate like 1 (MARCKSL1 protein); brain acid soluble protein 1 (BASP1 protein), or a fragment thereof, or any combination thereof; or (iii) both (i) and (ii).

7 . The EV of claim 3 , wherein:

(a) the antigen is linked to the first scaffold moiety on the luminal surface of the EV, and the adjuvant is linked to the second scaffold moiety on the luminal surface of the EV;

(b) the antigen is linked to the first scaffold moiety on the luminal surface of the EV, and the adjuvant is linked directly to the luminal surface of the EV;

(c) the antigen is linked to the first scaffold moiety on the luminal surface of the EV, and the adjuvant is in the lumen of the EV;

(d) the antigen is linked to the first scaffold moiety on the luminal surface of the EV, and the adjuvant is linked to the second scaffold moiety on the exterior surface of the EV;

(e) the antigen is linked to the first scaffold moiety on the luminal surface of the EV, and the adjuvant is linked directly to the exterior surface of the EV;

(f) the antigen is linked to the first scaffold moiety on the exterior surface of the EV, and the adjuvant is linked to the second scaffold moiety on the luminal surface of the EV surface;

(g) the antigen is linked to the first scaffold moiety on the exterior surface of the EV, and the adjuvant is linked directly to the luminal surface of the EV;

(h) the antigen is linked to the first scaffold moiety on the exterior surface of the EV, and the adjuvant is in the lumen of the EV;

(i) the antigen is linked to the first scaffold moiety on the exterior surface of the EV, and the adjuvant is linked to the second scaffold moiety on the exterior surface of the EV;

(j) the antigen is linked to the first scaffold moiety on the exterior surface of the EV, and the adjuvant is linked directly to the exterior surface of the EV;

(k) the antigen is in the lumen of the EV, and the adjuvant is linked to the first scaffold moiety on the luminal surface of the EV;

(l) the antigen is in the lumen of the EV, and the adjuvant is linked to the first scaffold moiety on the exterior surface of the EV;

(m) the antigen is linked directly to the luminal surface of the EV, and the adjuvant is linked to the first scaffold moiety on the luminal surface of the EV;

(n) the antigen is linked directly to the luminal surface of the EV, and the adjuvant is linked to a first scaffold moiety on the exterior surface of the EV;

(o) the antigen is linked directly to the exterior surface of the EV, and the adjuvant is linked to the first scaffold moiety on the luminal surface of the EV; or

(p) the antigen is linked directly to the exterior surface of the EV, and the adjuvant is linked to the first scaffold moiety on the exterior surface of the EV.

8 . The EV of claim 6 , wherein: (i) the Scaffold X is a PTGFRN protein or a fragment thereof; (ii) the Scaffold Y is a BASP1 protein or a fragment thereof; or (iii) both (i) and (ii).

9 . The EV of claim 5 , wherein: (i) the Scaffold X comprises an amino acid sequence set forth in SEQ ID NO: 33; (ii) the Scaffold Y comprises an amino acid sequence set forth in any one of SEQ ID NOs: 49-155 and 246-256; or (iii) both (i) and (ii).

10 . The EV of claim 1 , which further comprises an immune modulator; targeting moiety; or both.

11 . An isolated extracellular vesicle (EV) comprising (i) an antigen, (ii) a first scaffold moiety and (iii) an immune modulator, wherein the first scaffold moiety comprises a prostaglandin F2 receptor negative regulator (PTGFRN) protein or a fragment thereof.

12 . The EV of claim 11 , further comprising an adjuvant, targeting moiety, or both.

13 . The EV of claim 1 , which is an exosome.

14 . A pharmaceutical composition comprising the EV of claim 1 and a pharmaceutically acceptable carrier.

15 . A cell that produces the EV of claim 1 .

16 . An EV-drug conjugate comprising the EV of claim 1 .

17 . A method of making EVs comprising culturing the cell of claim 15 under a suitable condition and obtaining the EVs.

18 . A method of inducing an immune response in a subject in need thereof comprising administering the EV of claim 1 to the subject.

19 . A method of preventing or treating a disease in a subject in need thereof, comprising administering the EV of claim 1 , wherein the disease is associated with the antigen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: MONIZ, RAYMOND J.; MCCONNELL, RUSSELL E.; ROSS, NIKKI; MCCOY, CHRISTINE
To: CODIAK BIOSCIENCES, INC.
Reel/Frame 065495/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: CODIAK BIOSCIENCES, INC.
To: LONZA SALES AG
Reel/Frame 064251/0794 →
Continuity (8)
Provisional Application 62984146 · Mar 2, 2020
Provisional Application 62946280 · Dec 10, 2019
Provisional Application 62901166 · Sep 16, 2019
Provisional Application 62891048 · Aug 23, 2019
Provisional Application 62840348 · Apr 29, 2019
Provisional Application 62835437 · Apr 17, 2019
Provisional Application 62822008 · Mar 21, 2019
Related Publication 20220168415A1 · Jun 2, 2022
References Cited (110)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 7087229B2 · Zhao et al. · 2006 [cited by applicant]
US 7375078B2 · Feng · 2008 [cited by applicant]
US 7569657B2 · Zhao et al. · 2009 [cited by applicant]
US 7754681B2 · Feng · 2010 [cited by applicant]
US 8137695B2 · Rozema et al. · 2012 [cited by applicant]
US 8354455B2 · Satyam · 2013 [cited by applicant]
US 8426565B2 · Lahoud et al. · 2013 [cited by applicant]
US 8465730B1 · O'Lenick · 2013 [cited by applicant]
US 8617564B2 · Long et al. · 2013 [cited by applicant]
US 9695212B2 · Dubensky et al. · 2017 [cited by applicant]
US 9790494B2 · Uhlmann et al. · 2017 [cited by applicant]
US 9988431B2 · Lahoud et al. · 2018 [cited by applicant]
US 10011630B2 · Vernejoul et al. · 2018 [cited by applicant]
US 10195290B1 · Dooley et al. · 2019 [cited by applicant]
US 11992527B2 · Moniz et al. · 2024 [cited by applicant]
US 20030130189A1 · Senter et al. · 2003 [cited by applicant]
US 20050256030A1 · Feng · 2005 [cited by applicant]
US 20060269480A1 · Amir et al. · 2006 [cited by applicant]
US 20080085869A1 · Yamada et al. · 2008 [cited by applicant]
US 20100029585A1 · Howbert et al. · 2010 [cited by applicant]
US 20100092496A1 · Boyd et al. · 2010 [cited by applicant]
US 20100145036A1 · Sufi et al. · 2010 [cited by applicant]
US 20110182942A1 · Zollinger · 2011 [cited by applicant]
US 20120219615A1 · Hershberg et al. · 2012 [cited by applicant]
US 20130202707A1 · Ali et al. · 2013 [cited by applicant]
US 20140193849A1 · Narayanan et al. · 2014 [cited by applicant]
US 20180037639A1 · Crowe et al. · 2018 [cited by applicant]
US 20210322327A1 · Jang et al. · 2021 [cited by applicant]
US 20230263885A1 · Moniz et al. · 2023 [cited by applicant]
JP 2006518212A · 2006 [cited by applicant]
WO 2004073319A2 · 2004 [cited by applicant]
WO 2008115319A2 · 2008 [cited by applicant]
WO 2009030996A1 · 2009 [cited by applicant]
WO 2009088401A2 · 2009 [cited by applicant]
WO 2011044246A1 · 2011 [cited by applicant]
WO 2013053008A2 · 2013 [cited by applicant]
WO 2013185052A1 · 2013 [cited by applicant]
WO 2014093936A1 · 2014 [cited by applicant]
WO 2014179335A1 · 2014 [cited by applicant]
WO 2014179760A1 · 2014 [cited by applicant]
WO 2014189805A1 · 2014 [cited by applicant]
WO 2014189806A1 · 2014 [cited by applicant]
WO 2015017652A1 · 2015 [cited by applicant]
WO 2015077354A1 · 2015 [cited by applicant]
WO 2015185565A1 · 2015 [cited by applicant]
WO 2016096174A1 · 2016 [cited by applicant]
WO 2016096577A1 · 2016 [cited by applicant]
WO 2016120305A1 · 2016 [cited by applicant]
WO 2016145102A1 · 2016 [cited by applicant]
WO 2016184860A1 · 2016 [cited by applicant]
WO 2017027645A1 · 2017 [cited by applicant]
WO 2017027646A1 · 2017 [cited by applicant]
WO 2017075477A1 · 2017 [cited by applicant]
WO 2017161349A1 · 2017 [cited by applicant]
WO 2017175147A1 · 2017 [cited by applicant]
WO 2017175156A1 · 2017 [cited by applicant]
WO 2018100558A2 · 2018 [cited by applicant]
WO 2019040920A1 · 2019 [cited by applicant]
WO 2019099942A1 · 2019 [cited by applicant]
WO 2019183578A1 · 2019 [cited by applicant]
WO 2020191361A2 · 2020 [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/024023, European Patent Office, Netherlands, mailed on Sep. 23, 2020. [cited by applicant]
Aasland, R., et al., “Normalization of Nomenclature for Peptide Motifs as Ligands of Modular Protein Domains,” FEBS Letters 513(1):141-144 (2002). [cited by applicant]
Ahrens, S., et al., “F-Actin is an Evolutionarily Conserved Damage-associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells,” Immunity 36(4):635-645 (2012). [cited by applicant]
Arlehamn, et al., “Dissecting Mechanisms of Immunodominance to the Common Tuberculosis Antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ),” Journal of Immunology 188(10):5020-5031 (2012). [cited by applicant]
Besse, B., et al., “Dendritic Cell-derived Exosomes as Maintenance Immunotherapy After First Line Chemotherapy in NSCLC,” Oncoimmunology 5(4):e1071008 (2015). [cited by applicant]
Caculitan, N.G., et al., “Cathepsin B is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates,” Cancer Research 77(24):7027-7037 (2017). [cited by applicant]
Collin, M et al., “Human Dendritic Cell Subsets: An Update,” Immunology 154(1):3-20 (2018). [cited by applicant]
Corrales, L., et al., “Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity,” Cell Reports 11(7):1018-1030 (2015). [cited by applicant]
Dobeli, H., et al., “Role of the Carboxy-terminal Sequence on the Biological Activity of Human Interferon (IFN-y),” Journal of Biotechnology 7:199-216 (1988). [cited by applicant]
Doronina, S.O., et al., “Development of Potent Monoclonal Antibody Auristatin Conjugatesfor Cancer Therapy,” Nature Biotechnology 21(7):778-784 (2003). [cited by applicant]
Fu, J., et al., “STING Agonist Formulated Cancer Vaccines Can Cure Established TumorsResistant to PD-1 Blockade,” Science Translational Medicine 7(283):283ra52 (2015). [cited by applicant]
Gayle, R.B., III., et al., “Identification of Regions in Interleukin-1 Alpha Important forActivity,” The Journal of Biological Chemistry 268(29):22105-22111 (1993). [cited by applicant]
Gupta, S.C., et al., “Inhibiting NF-KB Activation by Small Molecules as a Therapeutic Strategy,” Biochimica Et Biophysica Acta 1799(10-12):775-787 (2010). [cited by applicant]
Hartlage, A.S., et al., “The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate TargetAntigen for Vaccine Development,” Cancer Immunology Research 3(7):787-794 (2015). [cited by applicant]
Huysamen, C., et al., “CLEC9A Is a Novel Activation C-type Lectin-like Receptor Expressedon BDCA3+ Dendritic Cells and a Subset of Monocytes,” The Journal of Biological Chemistry 283(24):16693-16701 (2008). [cited by applicant]
Kihara, Y., et al., “Lysophospholipid Receptors in Drug Discovery,” Experimental Cell Research 333(2):171-177 (2015). [cited by applicant]
Kuypers, F.A., et al., “Survival of Rabbit and Horse Erythrocytes in Vivo after Changing theFatty Acyl Composition of their Phosphatidylcholine,” Biochimica et Biophysica Acta 819(2):170-178 (1985). [cited by applicant]
Mei, B., et al., “Rational Design of a Fully active, Long-acting PEGylated Factor VIII for Hemophilia A Treatment,” Blood 116(2):270-279 (2010). [cited by applicant]
Miao, L., et al., “Delivery of mRNA Vaccines With Heterocyclic Lipids Increases Anti-tumorEfficacy by STING-Mediated Immune Cell Activation,” Nature Biotechnology 37(10):1174- 1185 (2019). [cited by applicant]
Morishita M. et al., “Exosome-based tumor antigens-adjuvant co-delivery utilizinggenetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.” Biomaterials 111:55-65 (2016). [cited by applicant]
Palmer, S.M., et al., “Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial ofBMS-986020, A Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis,” Chest 154(5):1061-1069 (2… [cited by applicant]
Papapetrou, E.P., et al., “Genetic Modification of Hematopoietic Stem Cells With Nonviral Systems: Past Progress and Future Prospects,” Gene Therapy 12(Suppl 1):S118-S130 (2005). [cited by applicant]
Pitt, J.M., et al., “Dendritic Cell-Derived Exosomes for Cancer Therapy,” The Journal of Clinical Investigation 126(4):1224-1232 (2016). [cited by applicant]
Reddy, J.A., et al., “Folate Receptor Specific Anti-tumor Activity of Folate-mitomycinConjugates,” Cancer Chemotherapy and Pharmacology 58(2):229-236 (2006). [cited by applicant]
Rist, M.J., et al., “T Cell Epitope Clustering in the Highly Immunogenic BZLF1 Antigen of Epstein-Barr Virus,” Journal of Virology 89(1):703-712 (2015). [cited by applicant]
Ron, D., et al., “Expression of Biologically Active Recombinant Keratinocyte Growth Factor.Structure/Function Analysis of Amino-terminal Truncation Mutants,” The Journal of Biological Chemistry 268(4):2984-2988 (1993). [cited by applicant]
Rosen, G., et al., “LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis,” European Respiratory Journal 50:PA1038 (2017). [cited by applicant]
Senti G., et al., “Intralymphatic Allergen Administration Renders Specific ImmunotherapyFaster and Safer: a Randomized Controlled Trial,” PNAS 105(46):17908-17912 (2008). [cited by applicant]
Trouet, A., et al., “A Covalent Linkage Between Daunorubicin and Proteins That Is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-carrier Conjugate: In Vitro and in Vivo Stu… [cited by applicant]
Umemoto, N., et al., “Preparation and in Vitro Cytotoxicity of a Methotrexate-Anti-MM46 Monoclonal Antibody Conjugate via An Oligopeptide Spacer,” International Journal of Cancer 43(4):677-684 (1989). [cited by applicant]
He, S., et al., “Structure of Nucleosome-Bound Human BAF Complex,” Science 367(6480):1-12 (2020). [cited by applicant]
Yan, Z., et al., “A Novel Peptide Targeting Clec9a on Dendritic Cell for Cancer Immunotherapy,” Oncotarget 7(26):40437-40450 (2016). [cited by applicant]
Yang, J., et al., “Characterization of the pH of Folate Receptor-containing Endosomes andthe Rate of Hydrolysis of Internalized Acid-labile Folate-drug Conjugates,” The Journal of Pharmacology and Experimental Therapeut… [cited by applicant]
Yuan, Q., et al., “A stimulus-responsive Magnetic Nanoparticle Drug Carrier: Magnetite Encapsulated by Chitosan-grafted-copolymer,” Acta Biomaterialia 4(4):1024-1037 (2008). [cited by applicant]
Zhang, J., et al., “Magnetic Drug-targeting Carrier Encapsulated with Thermosensitive SmartPolymer: Core-shell Nanoparticle Carrier and Drug Release Response,” Acta biomaterialia 3(6):838-850 (2007). [cited by applicant]
Zhang, J.G., et al., “The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments,” Immunity 36(4):646-657 (2012). [cited by applicant]
Zhou, L., et al., “Endosomal pH-activatable Poly(ethylene oxide)-graft-doxorubicin Prodrugs: Synthesis, Drug Release, and Biodistribution in Tumor-bearing Mice,” Biomacromolecules 12(5):1460-1467 (2011). [cited by applicant]
Grandi et al., “Synergistic Protective Activity of Tumor-Specific Epitopes Engineered inBacterial Outer Membrane Vesicles,” Frontiers in Oncology 7:1-12. [cited by applicant]
Chen, R., et al., “Exosomes in hepatocellular carcinoma: a new horizon,” Cell CommunSignal 17(1): 1, Biomed Central, United Kingdom (Jan. 2019). [cited by applicant]
Fantappie, L., et al., “Antibody-mediated immunity induced by engineered [cited by applicant]
Gnopo, Y.M.D., et al., “Designer outer membrane vesicles as immunomodulatory systems—Reprogramming bacteria for vaccine delivery,” Adv Drug Deliv Rev 114: 13 2-142, Elsevier, Netherlands (May 2017). [cited by applicant]
He, Y., et al., “Engineering a-fetoprotein-based gene vaccines to prevent and treathepatocellular carcinoma: review and future prospects,” Immunotherapy 6(6):725-736, Future Medicine, United Kingdom (Jun. 2014). [cited by applicant]
Kato, K., et al., “Cyclic GMP-AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA,” Annu Rev Biochem 86:541-566, Annual Reviews, United States (Jun. 2017). [cited by applicant]
Kitai, Y., et al., “DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity,” J Immunol 198( 4): 1649-1659, American Association of Im… [cited by applicant]
Koshy, S.T., et al., “Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy,” AdvBiosyst 1(1-2):1600013, Wiley, United States (Feb. 2017). [cited by applicant]
Ma, F., et al., “Positive feedback regulation of type I interferon by the interferon-stimulated gene STING,” EMBO Rep 16(2):202-212, Nature Portfolio, Germany (Feb. 2015). [cited by applicant]
Miyabe, H., et al., “A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy,” J Control Release 184:20-27, Elsevier, Netherlands (Jun. 2014). [cited by applicant]
Tan, K., et al., “Outer Membrane Vesicles: Current Status and Future Direction of These NovelVaccine Adjuvants,” Front Microbiol 9:783, Frontiers Media S.A., Switzerland (Apr. 2018). [cited by applicant]